Drug intelligence / Profile preview

darunavir + emtricitabine + lopinavir + ritonavir + tenofovir

Development stage: Unknown
Lead developer: Janssen Pharmaceutica
Modality: Small Molecules
Administration: Oral

Overview

This is a combination of five antiretroviral medications used for the treatment of HIV infection. The combination includes a protease inhibitor (darunavir), a nucleoside reverse transcriptase inhibitor (emtricitabine), another protease inhibitor (lopinavir), a pharmacokinetic enhancer (ritonavir), and another nucleoside reverse transcriptase inhibitor (tenofovir). These medications work together to prevent HIV from multiplying in the body by inhibiting different stages of the viral replication process.

Targets

CYP3A4 (Cytochrome P450 3A4)Human immunodeficiency virus type 1 reverse transcriptasePR (Progesterone receptor)

Beyond the preview

Go deeper on darunavir + emtricitabine + lopinavir + ritonavir + tenofovir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on darunavir + emtricitabine + lopinavir + ritonavir + tenofovir.

Explore the full profile